Peter A Merkel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2052517/publications.pdf

Version: 2024-02-01

312 papers	30,308 citations	6592 79 h-index	5519 163 g-index
327 all docs	327 docs citations	327 times ranked	19192 citing authors

#	Article	IF	Citations
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
2	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine, 2010, 363, 221-232.	13.9	2,275
3	Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis and Rheumatism, 2008, 58, 15-25.	6.7	1,918
4	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine, 2017, 376, 1921-1932.	13.9	682
5	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. New England Journal of Medicine, 2013, 369, 417-427.	13.9	611
6	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Annals of the Rheumatic Diseases, 2007, 66, 605-617.	0.5	524
7	Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data metaâ€analysis. Arthritis and Rheumatism, 2007, 56, 2789-2797.	6.7	521
8	Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis. Annals of Internal Medicine, 2007, 146, 621.	2.0	491
9	A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis and Rheumatism, 2002, 46, 1309-1318.	6.7	480
10	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. New England Journal of Medicine, 2020, 382, 622-631.	13.9	465
11	Avacopan for the Treatment of ANCA-Associated Vasculitis. New England Journal of Medicine, 2021, 384, 599-609.	13.9	461
12	ANCA-associated vasculitis. Nature Reviews Disease Primers, 2020, 6, 71.	18.1	443
13	Recombinant human antiâ€“transforming growth factor Î²1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis and Rheumatism, 2007, 56, 323-333.	6.7	415
14	A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score. Arthritis and Rheumatism, 2001, 44, 912-920.	6.7	400
15	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2011, 70, 32-38.	0.5	394
16	Drug-associated antineutrophil cytoplasmic antibodyâ€“positive vasculitis: Prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis and Rheumatism, 2000, 43, 405.	6.7	390
17	Guide to Bone Health and Disease in Cystic Fibrosis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1888-1896.	1.8	388
18	Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. European Journal of Internal Medicine, 2015, 26, 545-553.	1.0	371

#	Article	IF	Citations
19	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 11-18.	1.0	321
20	Clinical research for rare disease: Opportunities, challenges, and solutions. Molecular Genetics and Metabolism, 2009, 96, 20-26.	0.5	320
21	Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. Rheumatology, 2012, 51, 100-109.	0.9	285
22	Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Annals of Internal Medicine, 2005, 142, 620.	2.0	277
23	Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis and Rheumatism, 2002, 46, 2410-2420.	6.7	272
24	A Randomized, Doubleâ€Blind Trial of Abatacept (CTLAâ€4Ig) for the Treatment of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 837-845.	2.9	271
25	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2021, 73, 1366-1383.	2.9	249
26	Granulomatosis with Polyangiitis (Wegener's): An alternative name for Wegener's Granulomatosis. Arthritis and Rheumatism, 2011, 63, 863-864.	6.7	244
27	¹⁸Fâ€Fluorodeoxyglucoseâ€“Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis. Arthritis and Rheumatology, 2018, 70, 439-449.	2.9	241
28	Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis. Annals of Internal Medicine, 2007, 147, 611.	2.0	234
29	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis and Rheumatology, 2021, 73, 1349-1365.	2.9	231
30	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Annals of the Rheumatic Diseases, 2012, 71, 1329-1334.	0.5	218
31	Insulin Resistance and Hyperinsulinemia in Patients with Thalassemia Major Treated by Hypertransfusion. New England Journal of Medicine, 1988, 318, 809-814.	13.9	214
32	Diagnostic imaging in Takayasu arteritis. Current Opinion in Rheumatology, 2004, 16, 31-37.	2.0	207
33	Apremilast for BehÃ§etâ€™s Syndrome â€” A Phase 2, Placebo-Controlled Study. New England Journal of Medicine, 2015, 372, 1510-1518.	13.9	204
34	Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibodyâ€“associated vasculitis: A metaâ€analysis. Arthritis Care and Research, 2010, 62, 1166-1173.	1.5	200
35	Nomenclature of Cutaneous Vasculitis. Arthritis and Rheumatology, 2018, 70, 171-184.	2.9	200
36	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Annals of the Rheumatic Diseases, 2016, 75, 1166-1169.	0.5	196

#	Article	IF	Citations
37	Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Annals of the Rheumatic Diseases, 2013, 72, 1003-1010.	0.5	183
38	Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis. American Journal of Kidney Diseases, 2011, 57, 566-574.	2.1	179
39	Prevalence of Antineutrophil Cytoplasmic Antibodies in a Large Inception Cohort of Patients with Connective Tissue Disease. Annals of Internal Medicine, 1997, 126, 866.	2.0	176
40	Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study. Arthritis and Rheumatism, 1998, 41, 670-677.	6.7	175
41	Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism, 2005, 52, 2168-2178.	6.7	171
42	Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis and Rheumatism, 2000, 43, 226-231.	6.7	165
43	The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. American Journal of Medicine, 1996, 101, 576-583.	0.6	158
44	ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clinical and Experimental Nephrology, 2013, 17, 619-621.	0.7	158
45	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Annals of the Rheumatic Diseases, 2022, 81, 309-314.	0.5	157
46	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care and Research, 2011, 63, 588-596.	1.5	147
47	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Annals of the Rheumatic Diseases, 2022, 81, 315-320.	0.5	145
48	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	2.6	144
49	Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. American Journal of Human Genetics, 2013, 93, 298-305.	2.6	143
50	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1744-1750.	0.5	139
51	Association of Granulomatosis With Polyangiitis (Wegener's) With HLAâ€“DPB1*04 and SEMA6A Gene Variants: Evidence From Genomeâ€Wide Analysis. Arthritis and Rheumatism, 2013, 65, 2457-2468.	6.7	138
52	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, doubleâ€blind, placeboâ€controlled trial. Arthritis and Rheumatism, 2009, 60, 1102-1111.	6.7	137
53	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. Journal of the American Society of Nephrology: JASN, 2015, 26, 976-985.	3.0	137
54	Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis. Annals of Internal Medicine, 2014, 160, 73-80.	2.0	133

#	Article	IF	Citations
55	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. Arthritis and Rheumatology, 2016, 68, 1700-1710.	2.9	132
56	A Randomized, Doubleâ€Blind Trial of Abatacept (CTLAâ€4Ig) for the Treatment of Takayasu Arteritis. Arthritis and Rheumatology, 2017, 69, 846-853.	2.9	131
57	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 1054-1066.	2.9	130
58	Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. Journal of Rheumatology, 2015, 42, 1213-1217.	1.0	129
59	An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Annals of the Rheumatic Diseases, 2014, 73, 1376-1379.	0.5	128
60	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	0.9	128
61	Neutrophilâ€Related Gene Expression and Lowâ€Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2015, 67, 1922-1932.	2.9	116
62	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Annals of the Rheumatic Diseases, 2022, 81, 321-326.	0.5	112
63	Cocaine-associated cerebral vasculitis. Seminars in Arthritis and Rheumatism, 1995, 25, 172-183.	1.6	110
64	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis and Rheumatism, 2008, 59, 699-705.	6.7	109
65	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2013, 72, 1342-1350.	0.5	109
66	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Seminars in Arthritis and Rheumatism, 2016, 45, 475-482.	1.6	109
67	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. Journal of Rheumatology, 2005, 32, 832-40.	1.0	107
68	Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. Annals of the Rheumatic Diseases, 2011, 70, 704-704.	0.5	106
69	The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis. Journal of Rheumatology, 2011, 38, 1480-1486.	1.0	105
70	Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. Journal of Rheumatology, 2003, 30, 1630-47.	1.0	104
71	Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo Clinic Proceedings, 2021, 96, 2694-2707.	1.4	103
72	Comparison of magnetic resonance angiography and¹⁸F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Annals of the Rheumatic Diseases, 2018, 77, 1165-1171.	0.5	101

#	Article	IF	Citations
73	Metabolic pathways and immunometabolism in rare kidney diseases. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212935.	0.5	101
74	Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. Annals of the Rheumatic Diseases, 2015, 74, 993-997.	0.5	100
75	Trends in Longâ€Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis With Renal Disease. Arthritis and Rheumatology, 2016, 68, 1711-1720.	2.9	97
76	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2016, 315, 1975.	3.8	95
77	MultiPLIER: A Transfer Learning Framework for Transcriptomics Reveals Systemic Features of Rare Disease. Cell Systems, 2019, 8, 380-394.e4.	2.9	92
78	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis Care and Research, 2021, 73, 1088-1105.	1.5	90
79	Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?. Rheumatology, 2017, 56, 1154-1161.	0.9	89
80	Alpha₁â€antitrypsin deficiencyâ€“related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis and Rheumatism, 2010, 62, 3760-3767.	6.7	87
81	Cardiac Involvement in Granulomatosis with Polyangiitis. Journal of Rheumatology, 2015, 42, 1209-1212.	1.0	87
82	Patientâ€reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care and Research, 2010, 62, 1639-1645.	1.5	86
83	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis: A Randomized Controlled Study. Arthritis and Rheumatology, 2019, 71, 952-963.	2.9	82
84	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. Journal of Allergy and Clinical Immunology, 2019, 143, 2170-2177.	1.5	82
85	Drugs associated with vasculitis. Current Opinion in Rheumatology, 1998, 10, 45-50.	2.0	81
86	Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda. Journal of Rheumatology, 2011, 38, 1471-1479.	1.0	79
87	Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2015, 67, 1361-1368.	2.9	79
88	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	2.6	78
89	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. Arthritis Care and Research, 2020, 72, 1615-1624.	1.5	77
90	Myeloperoxidaseâ€“Antineutrophil Cytoplasmic Antibody (ANCA)â€“Positive and ANCAâ€Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. Arthritis and Rheumatology, 2016, 68, 2945-2952.	2.9	75

#	Article	IF	Citations
91	IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20736-20741.	3.3	74
92	Thromboembolic disease in vasculitis. Current Opinion in Rheumatology, 2009, 21, 41-46.	2.0	73
93	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2022, 74, 393-399.	2.9	71
94	Patterns and predictors of change in outcome measures in clinical trials in scleroderma: An individual patient metaâ€analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis and Rheumatism, 2012, 64, 3420-3429.	6.7	69
95	Comparison of Treatment Response in Idiopathic and Connective Tissue Diseaseâ€“associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1111-1117.	2.5	67
96	Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials, 2017, 18, 112.	0.7	65
97	Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. ACR Open Rheumatology, 2020, 2, 662-671.	0.9	64
98	Systemic sclerosis - continuing progress in developing clinical measures of response. Journal of Rheumatology, 2007, 34, 1194-200.	1.0	64
99	Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care and Research, 2011, 63, 1055-1061.	1.5	63
100	The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet Journal of Rare Diseases, 2016, 11, 66.	1.2	62
101	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. Arthritis and Rheumatology, 2022, 74, 400-406.	2.9	62
102	Patient-powered research networks: building capacity for conducting patient-centered clinical outcomes research. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 583-586.	2.2	61
103	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care and Research, 2021, 73, 1071-1087.	1.5	61
104	Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care and Research, 2011, 63, 1777-1781.	1.5	60
105	Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and Rheumatism, 2011, 63, 3988-3997.	6.7	59
106	Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study. Journal of Rheumatology, 2016, 43, 1559-1565.	1.0	59
107	Solid malignancies among etanerceptâ€treated patients with granulomatosis with polyangiitis (Wegener's): Longâ€term followup of a multicenter longitudinal cohort. Arthritis and Rheumatism, 2011, 63, 2495-2503.	6.7	58
108	Outcome measures in systemic sclerosis: An update on instruments and current research. Current Rheumatology Reports, 2007, 9, 151-157.	2.1	57

#	Article	IF	Citations
109	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	0.9	56
110	Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. Journal of Rheumatology, 2021, 48, 603-607.	1.0	56
111	Assessment of disease activity and progression in Takayasu's arteritis. Clinical and Experimental Rheumatology, 2011, 29, S86-91.	0.4	56
112	Outcome Measures Used in Clinical Trials for BehÃ§et Syndrome: A Systematic Review. Journal of Rheumatology, 2014, 41, 599-612.	1.0	54
113	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. Journal of Clinical Epidemiology, 2014, 67, 706-714.	2.4	52
114	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology, 2015, 54, 1351-1359.	0.9	52
115	Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Scientific Reports, 2017, 7, 43953.	1.6	52
116	Association of Vascular Physical Examination Findings and Arteriographic Lesions in Large Vessel Vasculitis. Journal of Rheumatology, 2012, 39, 303-309.	1.0	51
117	Illness Perceptions and Fatigue in Systemic Vasculitis. Arthritis Care and Research, 2013, 65, 1835-1843.	1.5	51
118	Using patient-reported outcomes and PROMIS in research and clinical applications: experiences from the PCORI pilot projects. Quality of Life Research, 2016, 25, 2109-2116.	1.5	51
119	Infections and the risk of incident giant cell arteritis: a population-based, case-control study. Annals of the Rheumatic Diseases, 2017, 76, 1031-1035.	0.5	51
120	Hearing Loss in WegenerÊ¼s Granulomatosis. Otology and Neurotology, 2004, 25, 833-837.	0.7	50
121	The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 251-257.	2.2	50
122	Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial. JMIR Research Protocols, 2020, 9, e16664.	0.5	50
123	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2022, 74, 386-392.	2.9	50
124	Granulomatosis with Polyangiitis (Wegener's). Journal of the American Society of Nephrology: JASN, 2011, 22, 587-588.	3.0	49
125	Assessment of healthâ€related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care and Research, 2012, 64, 273-279.	1.5	49
126	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	1.5	49

#	Article	IF	Citations
127	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2018, 70, 1114-1121.	2.9	49
128	Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis and Rheumatism, 2000, 43, 2488-2492.	6.7	48
129	Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibodyâ€“associated vasculitis. Rheumatology, 2017, 56, 1962-1969.	0.9	48
130	Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis. Journal of Rheumatology, 2020, 47, 99-107.	1.0	48
131	Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. Arthritis and Rheumatism, 2008, 59, 746-753.	6.7	47
132	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Annals of the Rheumatic Diseases, 2011, 70, 80-85.	0.5	47
133	Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Rheumatology, 2017, 44, 1468-1475.	1.0	47
134	Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmunity Reviews, 2020, 19, 102495.	2.5	47
135	Readability and Suitability Assessment of Patient Education Materials in Rheumatic Diseases. Arthritis Care and Research, 2013, 65, 1702-1706.	1.5	46
136	Genetics of vasculitis. Current Opinion in Rheumatology, 2010, 22, 157-163.	2.0	45
137	Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegenerâ€™s Granulomatosis. Journal of Rheumatology, 2011, 38, 1048-1054.	1.0	45
138	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3â€“Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 185-193.	2.9	45
139	Outcome measurements in scleroderma: results from a delphi exercise. Journal of Rheumatology, 2007, 34, 501-9.	1.0	45
140	Pregnancy Outcomes Among Patients With Vasculitis. Arthritis Care and Research, 2013, 65, 1370-1374.	1.5	44
141	Clinical course of 602 patients with Takayasu's arteritis: comparison between Childhood-onset versus adult onset disease. Rheumatology, 2021, 60, 2246-2255.	0.9	44
142	Alternating antineutrophil cytoplasmic antibody specificity: Drug-induced vasculitis in a patient with Wegener's granulomatosis. Arthritis and Rheumatism, 1999, 42, 384-388.	6.7	43
143	A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. Arthritis and Rheumatism, 2005, 52, 902-910.	6.7	43
144	Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). Journal of Rheumatology, 2009, 36, 2356-2361.	1.0	43

#	Article	IF	Citations
145	Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study. Journal of Rheumatology, 2017, 44, 84-90.	1.0	43
146	Arterial lesions in giant cell arteritis: A longitudinal study. Seminars in Arthritis and Rheumatism, 2019, 48, 707-713.	1.6	43
147	The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ, The, 2022, 376, e064604.	3.0	42
148	Systemic vasculitis--is it time to reclassify?. Rheumatology, 2011, 50, 643-645.	0.9	41
149	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, 2019, 71, 964-971.	2.9	41
150	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. Journal of Rheumatology, 2013, 40, 1905-1912.	1.0	40
151	Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology International, 2018, 38, 675-682.	1.5	40
152	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2020, 35, 283-291.	0.4	40
153	Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Rheumatology, 2013, 40, 674-683.	1.0	39
154	Comorbidities in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis versus the General Population. Journal of Rheumatology, 2016, 43, 1553-1558.	1.0	38
155	Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212713.	0.5	38
156	The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. Journal of Rheumatology, 2016, 43, 1078-1084.	1.0	37
157	Characterisation of the nasal microbiota in granulomatosis with polyangiitis. Annals of the Rheumatic Diseases, 2018, 77, 1448-1453.	0.5	37
158	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. Rheumatology, 2019, 58, 2203-2211.	0.9	37
159	Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period. Journal of Cystic Fibrosis, 2015, 14, 526-532.	0.3	36
160	Evaluation of a simple office-based strategy for increasing influenza vaccine administration and the effect of differing reimbursement plans on the patient acceptance rate. Journal of General Internal Medicine, 1994, 9, 679-683.	1.3	35
161	Heterotopic ossification in the setting of neuromuscular blockade. Arthritis and Rheumatism, 1997, 40, 1619-1627.	6.7	35
162	Domains of health-related quality of life important to patients with giant cell arteritis. Arthritis and Rheumatism, 2003, 49, 819-825.	6.7	35

#	Article	IF	Citations
163	Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9. Journal of Rheumatology, 2009, 36, 2362-2368.	1.0	35
164	Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). PLoS ONE, 2015, 10, e0121737.	1.1	35
165	The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. Journal of Rheumatology, 2007, 34, 2446-50.	1.0	35
166	Rheumatic disease and cystic fibrosis. Arthritis and Rheumatism, 1999, 42, 1563-1571.	6.7	34
167	Nutrient Status of Adults with Cystic Fibrosis. Journal of the American Dietetic Association, 2007, 107, 2114-2119.	1.3	34
168	Outcome measures for Takayasu's arteritis. Current Opinion in Rheumatology, 2015, 27, 32-37.	2.0	34
169	Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	34
170	Sequenceâ€Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. Arthritis and Rheumatology, 2021, 73, 512-519.	2.9	34
171	Metaâ€analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 3463-3471.	6.7	33
172	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. Journal of Rheumatology, 2015, 42, 2465-2469.	1.0	33
173	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. Journal of Rheumatology, 2017, 44, 1933-1937.	1.0	33
174	The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. Journal of Rheumatology, 2017, 44, 1515-1521.	1.0	33
175	Derivation of an angiographically based classification system in Takayasuâ€™s arteritis: an observational study from India and North America. Rheumatology, 2020, 59, 1118-1127.	0.9	33
176	Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort. Arthritis and Rheumatology, 2020, 72, 667-676.	2.9	33
177	The future of damage assessment in vasculitis. Journal of Rheumatology, 2007, 34, 1357-71.	1.0	33
178	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis and Rheumatology, 2021, 73, 1384-1393.	2.9	32
179	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. Journal of Rheumatology, 2005, 32, 2488-95.	1.0	32
180	The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time. Seminars in Arthritis and Rheumatism, 2022, 55, 152010.	1.6	32

#	Article	IF	Citations
181	Current Status of Outcome Measure Development in Vasculitis. Journal of Rheumatology, 2014, 41, 593-598.	1.0	31
182	A small n sequential multiple assignment randomized trial design for use in rare disease research. Contemporary Clinical Trials, 2016, 46, 48-51.	0.8	31
183	Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2020, 72, 1741-1747.	2.9	31
184	Development and validation of caseâ€finding algorithms for the identification of patients with antiâ€neutrophil cytoplasmic antibodyâ€associated vasculitis in large healthcare administrative databases. Pharmacoepidemiology and Drug Safety, 2016, 25, 1368-1374.	0.9	29
185	Patient involvement in medical research: what patients and physicians learn from each other. Orphanet Journal of Rare Diseases, 2019, 14, 21.	1.2	29
186	Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's). Arthritis and Rheumatology, 2014, 66, 428-432.	2.9	28
187	Evaluation of damage in giant cell arteritis. Rheumatology, 2018, 57, 322-328.	0.9	28
188	Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis. Annals of the Rheumatic Diseases, 2018, 77, 589-595.	0.5	27
189	Correlates and Responsiveness to Change of Measures of Skin and Musculoskeletal Disease in Early Diffuse Systemic Sclerosis. Arthritis Care and Research, 2014, 66, 1731-1739.	1.5	26
190	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	2.6	26
191	Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2015, 67, 535-544.	2.9	25
192	Developing a Core Set of Outcome Measures for BehÃ§et Disease: Report from OMERACT 2016. Journal of Rheumatology, 2017, 44, 1750-1753.	1.0	25
193	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1888-1893.	2.9	25
194	Patterns of clinical presentation in Takayasu's arteritis. Seminars in Arthritis and Rheumatism, 2020, 50, 576-581.	1.6	25
195	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibodyâ€“associated Vasculitis. Journal of Rheumatology, 2017, 44, 1529-1535.	1.0	25
196	Measurement of functional status, self-assessment, and psychological well-being in scleroderma. Current Opinion in Rheumatology, 1998, 10, 589-594.	2.0	24
197	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. Analytical Chemistry, 2016, 88, 6317-6325.	3.2	24
198	Patient-Reported Outcomes in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 140-148.	2.2	24

#	Article	IF	Citations
199	Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. Steroids, 2018, 140, 159-166.	0.8	24
200	Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. Patient Related Outcome Measures, 2018, Volume 9, 17-34.	0.7	24
201	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. Journal of Autoimmunity, 2019, 105, 102302.	3.0	24
202	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. Journal of Rheumatology, 2019, 46, 1198-1201.	1.0	24
203	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. Journal of Medical Internet Research, 2017, 19, e50.	2.1	24
204	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	1.8	23
205	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1879-1887.	2.9	23
206	Outcome Measures in Large Vessel Vasculitis: Relationship Between Patientâ€, Physicianâ€, Imagingâ€, and Laboratoryâ€Based Assessments. Arthritis Care and Research, 2020, 72, 1296-1304.	1.5	23
207	Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibodyâ€“associated Vasculitis Using the OMERACT Process. Journal of Rheumatology, 2015, 42, 2204-2209.	1.0	22
208	Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 176-184.	2.9	22
209	Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi Exercise. Journal of Rheumatology, 2017, 44, 1928-1932.	1.0	22
210	Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations. Journal of Rheumatology, 2007, 34, 1027-31.	1.0	22
211	Reliability, validity and responsiveness to change of the Saint Georgeâ€™s Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. Rheumatology, 2015, 54, 1369-1379.	0.9	21
212	The Pharmacogenomic Association of FcÎ³ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 169-175.	2.9	21
213	Core Set of Domains for Outcome Measures in BehÃ§et's Syndrome. Arthritis Care and Research, 2022, 74, 691-699.	1.5	21
214	Clinical Manifestations and Longâ€Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. ACR Open Rheumatology, 2021, 3, 404-412.	0.9	21
215	The informational needs of patients with ANCA-associated vasculitis--development of an informational needs questionnaire. Rheumatology, 2014, 53, 1414-1421.	0.9	20
216	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. Journal of Rheumatology, 2014, 41, 994-999.	1.0	20

#	Article	IF	Citations
217	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology, 2018, 57, 639-650.	0.9	20
218	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. Journal of Rheumatology, 2020, 47, 1001-1010.	1.0	20
219	A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment. BMC Medical Research Methodology, 2020, 20, 58.	1.4	20
220	Diagnostic delays in vasculitis and factors associated with time to diagnosis. Orphanet Journal of Rare Diseases, 2021, 16, 184.	1.2	20
221	Antineutrophil Cytoplasmic Antibodies, Autoimmune Neutropenia, and Vasculitis. Seminars in Arthritis and Rheumatism, 2011, 41, 424-433.	1.6	19
222	Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVIDâ€19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease. ACR Open Rheumatology, 2021, 3, 381-389.	0.9	19
223	Current Status, Goals, and Research Agenda for Outcome Measures Development in BehÃ§et Syndrome: Report from OMERACT 2014. Journal of Rheumatology, 2015, 42, 2436-2441.	1.0	18
224	Noninfectious Ascending Aortitis: Staying Ahead of the Curve. Journal of Rheumatology, 2009, 36, 2137-2140.	1.0	17
225	Brief Report: Defining the Nasal Transcriptome in Granulomatosis With Polyangiitis (Wegener's). Arthritis and Rheumatology, 2015, 67, 2233-2239.	2.9	17
226	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. Seminars in Arthritis and Rheumatism, 2020, 50, 1314-1325.	1.6	17
227	Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis. PLoS ONE, 2012, 7, e30197.	1.1	16
228	The association of vascular risk factors with visual loss in giant cell arteritis. Rheumatology, 2017, 56, kew397.	0.9	16
229	Pulmonary involvement in primary systemic vasculitides. Rheumatology, 2021, 61, 319-330.	0.9	16
230	Medication Interruptions and Subsequent Disease Flares During the <scp>COVID</scp>â€19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. Arthritis Care and Research, 2022, 74, 733-740.	1.5	16
231	Causal Attributions about Disease Onset and Relapse in Patients with Systemic Vasculitis. Journal of Rheumatology, 2014, 41, 923-930.	1.0	15
232	Body composition, lung function, and prevalent and progressive bone deficits among adults with cystic fibrosis. Joint Bone Spine, 2016, 83, 207-211.	0.8	15
233	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. American Journal of Nephrology, 2017, 46, 231-238.	1.4	15
234	Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis in the US. Arthritis Care and Research, 2017, 69, 1377-1383.	1.5	15

#	Article	IF	Citations
235	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Care and Research, 2021, 73, 1061-1070.	1.5	15
236	Scleroderma--developing measures of response. Journal of Rheumatology, 2005, 32, 2477-80.	1.0	15
237	Data linkages between patient-powered research networks and health plans: a foundation for collaborative research. Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 594-602.	2.2	14
238	Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. Trials, 2020, 21, 362.	0.7	14
239	Dynamic Changes in the Nasal Microbiome Associated With Disease Activity in Patients With Granulomatosis WithÂPolyangiitis. Arthritis and Rheumatology, 2021, 73, 1703-1712.	2.9	14
240	Correction of Hyperinsulinemia by Glyburide Treatment in Nondiabetic Patients with Thalassemia Major. Pediatric Research, 1993, 33, 497-500.	1.1	13
241	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Care and Research, 2016, 68, 167-178.	1.5	13
242	An interim report of the Scleroderma Clinical Trials Consortium working groups. Journal of Scleroderma and Related Disorders, 2019, 4, 17-27.	1.0	13
243	Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions. Patient, 2021, 14, 699-710.	1.1	13
244	Clinical Characteristics of an Internet-Based Cohort of Patient-Reported Diagnosis of Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Observational Study. Journal of Medical Internet Research, 2020, 22, e17231.	2.1	13
245	Adverse Events in Connective Tissue Diseaseâ€“Associated Pulmonary Arterial Hypertension. Arthritis and Rheumatology, 2015, 67, 2457-2465.	2.9	12
246	Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2018, 70, 2077-2086.	2.9	12
247	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. Frontiers in Immunology, 2020, 11, 2053.	2.2	12
248	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, 2021, 6, 66-76.	1.0	12
249	Response to: Correspondence on a€ 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitisâ€™ by Joanna C Robson et al and â€˜2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitisâ€™ by Ravi Suppiah et al. Annals of the Rheumatic Diseases, 2022, , annrheumdis-2022-222362.	0.5	12
250	Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. Arthritis Research and Therapy, 2022, 24, .	1.6	12
251	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis Care and Research, 2017, 69, 1004-1010.	1.5	11
252	Longâ€Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis. Arthritis Care and Research, 2020, 73, 1372-1378.	1.5	11

#	Article	IF	Citations
253	Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic sclerosis-related digital vasculopathy: A systematic literature review. Seminars in Arthritis and Rheumatism, 2020, 50, 1114-1130.	1.6	11
254	Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review. BMJ Open, 2022, 12, e050507.	0.8	11
255	Obinutuzumab as treatment for ANCA-associated vasculitis. Rheumatology, 2022, 61, 3814-3817.	0.9	11
256	Effects of the COVIDâ€19 Pandemic on Patients Living With Vasculitis. ACR Open Rheumatology, 2021, 3, 17-24.	0.9	10
257	Patient Perceptions and Preferences Regarding Telemedicine for Autoimmune Rheumatic Diseases Care During the <scp>COVID</scp>â€19 Pandemic. Arthritis Care and Research, 2022, 74, 1049-1057.	1.5	10
258	Use of 18F-fluorodeoxyglucose positron emission tomography to standardize clinical trial recruitment in Takayasuâ€™s arteritis. Rheumatology, 2022, 61, 4047-4055.	0.9	10
259	Evaluation and treatment of vasculitis in the critically ill patient. Critical Care Clinics, 2002, 18, 321-344.	1.0	9
260	Mapping of the Outcome Measures in Rheumatology Core Set for Antineutrophil Cytoplasmic Antibodyâ€Associated Vasculitis to the International Classification of Function, Disability and Health. Arthritis Care and Research, 2015, 67, 255-263.	1.5	9
261	Diffuse atrophic papules and plaques, intermittent abdominal pain, paresthesias, and cardiac abnormalities in a 55-year-old woman. Journal of the American Academy of Dermatology, 2016, 75, 1274-1277.	0.6	9
262	Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes . Patient Related Outcome Measures, 2019, Volume 10, 37-42.	0.7	9
263	Defining disease activity and damage in patients with small-vessel vasculitis. Cleveland Clinic Journal of Medicine, 2012, 79, S11-S15.	0.6	9
264	Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020. Seminars in Arthritis and Rheumatism, 2021, 51, 640-643.	1.6	8
265	Case 31-2008. New England Journal of Medicine, 2008, 359, 1603-1614.	13.9	7
266	Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma. Journal of Scleroderma and Related Disorders, 2020, 5, 167-171.	1.0	7
267	Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features. American Journal of Pathology, 2020, 190, 1438-1448.	1.9	7
268	Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health. Journal of Rheumatology, 2019, 46, 1415-1420.	1.0	7
269	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight, 2021, 6, .	2.3	7
270	Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 40-44.	0.4	7

#	Article	IF	Citations
271	Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review. Rheumatology, 2022, 61, 4603-4618.	0.9	7
272	A woman with severe lupus nephritis and difficult to control diabetes mellitus. Arthritis Care and Research, 2011, 63, 623-629.	1.5	6
273	Clinical image: Spinal gout presenting as acute low back pain. Arthritis and Rheumatism, 2013, 65, n/a-n/a.	6.7	6
274	Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis. Journal of Autoimmunity, 2015, 59, 43-52.	3.0	6
275	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. PLoS ONE, 2018, 13, e0205768.	1.1	6
276	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. Journal of Rheumatology, 2019, 46, 928-934.	1.0	6
277	Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. JCI Insight, 2020, 5, .	2.3	6
278	Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with <scp>ANCAâ€Associated</scp> Vasculitis. ACR Open Rheumatology, 2022, 4, 168-176.	0.9	6
279	Health-related outcomes of importance to patients with Takayasu's arteritis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 51-57.	0.4	6
280	Skin ulcers in a patient with SjÃ¶gren's syndrome. Arthritis Care and Research, 2010, 62, 1040-1046.	1.5	5
281	Alcohol-induced vasculitis: Case report and commentary. Journal of the American Academy of Dermatology, 2014, 70, e42-e43.	0.6	5
282	Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 202-208.	0.4	5
283	Severe Small-Vessel Vasculitis Temporally Associated With Administration of Ustekinumab. Journal of Drugs in Dermatology, 2016, 15, 359-62.	0.4	5
284	Patient-reported outcomes in Takayasu's arteritis. Presse Medicale, 2017, 46, e225-e227.	0.8	4
285	Ascending Aortic Aneurysm Secondary to Isolated Noninfectious Ascending Aortitis. Journal of Clinical Rheumatology, 2019, 25, 186-194.	0.5	4
286	Targeted Program in an Academic Rheumatology Practice to Improve Compliance With Opioid Prescribing Guidelines for the Treatment of Chronic Pain. Arthritis Care and Research, 2021, 73, 1425-1429.	1.5	4
287	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. Seminars in Arthritis and Rheumatism, 2021, 51, 1134-1138.	1.6	4
288	Impact of vasculitis on employment and income. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 58-64.	0.4	4

#	Article	IF	Citations
289	Patients' experiences with BehÃ§et's syndrome: structured interviews among patients with different types of organ involvement. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 28-34.	0.4	4
290	Composite outcomes at OMERACT: Multi-outcome domains and composite outcome domains. Seminars in Arthritis and Rheumatism, 2021, 51, 1370-1377.	1.6	3
291	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 98-101.	0.4	3
292	Efficacy of leflunomide in the treatment of vasculitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 114-118.	0.4	3
293	L50. The future of international clinical trials in vasculitis. Presse Medicale, 2013, 42, 637-641.	0.8	2
294	Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis. Annals of Internal Medicine, 2014, 161, 230.	2.0	2
295	Harnessing health plan enrollee data to boost membership in patient-powered research networks. BMC Health Services Research, 2020, 20, 462.	0.9	2
296	Hypothyroidism in vasculitis. Rheumatology, 2022, 61, 2942-2950.	0.9	2
297	Early development of new cardiovascular risk factors in the systemic vasculitides. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 126-134.	0.4	2
298	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis. Seminars in Arthritis and Rheumatism, 2022, 55, 152021.	1.6	2
299	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. Interactive Journal of Medical Research, 2022, 11, e27273.	0.6	2
300	P10. Review of the expert panel methodology in the diagnostic and classification criteria for vasculitis study: a pilot study. Rheumatology, 2014, 53, i15-i16.	0.9	1
301	Comment on: Derivation of an angiographically based classification system in Takayasuâ€™s arteritis: reply. Rheumatology, 2020, 59, 1184-1185.	0.9	1
302	Response to: â€˜Correspondence on â€˜Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitisâ€™â€™ by Parikh et al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2020-219329.	0.5	1
303	Multifocal neutrophilic meningoencephalitis: a novel disorder responsive to anakinra. Journal of Neurology, 2021, 268, 2995-2999.	1.8	1
304	Identifying Clinical Risk Factors for Opioid Use Disorder using a Distributed Algorithm to Combine Real-World Data from a Large Clinical Data Research Network. AMIA ... Annual Symposium proceedings, 2020, 2020, 1220-1229.	0.2	1
305	317.â€ƒRe-Appraisal of the 1990 American College of Rheumatology Classification Criteria for Systemic Vasculitis: Analysis of Data from the Diagnostic and Classification Criteria in Vasculitis Study. Rheumatology, 0, , .	0.9	0
306	Reply. Arthritis and Rheumatology, 2017, 69, 1505-1506.	2.9	0

#	Article	IF	Citations
307	Composition corporelle, fonction pulmonaire et perte progressive de masse osseuse chez lâ€™adulte souffrant de mucoviscidose. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 51-56.	0.0	0
308	Reply. Arthritis and Rheumatology, 2021, 73, 1089-1089.	2.9	0
309	P158â€ƒPerformance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic-related digital vasculopathy: a systematic literature review. Rheumatology, 2021, 60, .	0.9	0
310	FC 032THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WITH RENAL DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
311	Reply. Arthritis and Rheumatology, 2022, 74, 545-546.	2.9	0
312	FC057: Incidence of Infections in the Avacopan Group Versus Prednisone Group in Anca-Associated Vasculitis, Results from the Phase 3 Advocate Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0